These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34191401)

  • 1. Current status of oral antidiabetic drug prescribing patterns based on the body mass index for Japanese type 2 diabetes mellitus patients and yearly changes in diabetologists' prescribing patterns from 2002 to 2019 (JDDM61).
    Yagi N; Komiya I; Arai K; Oishi M; Fukumoto Y; Shirabe S; Yokoyama H; Yamazaki K; Sugimoto H; Maegawa H;
    J Diabetes Investig; 2022 Jan; 13(1):65-73. PubMed ID: 34191401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in antidiabetic prescription patterns in Japan from 2005 to 2011.
    Kohro T; Yamazaki T; Sato H; Harada K; Ohe K; Komuro I; Nagai R
    Int Heart J; 2013; 54(2):93-7. PubMed ID: 23676369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing use of antidiabetic drugs in the UK: trends in prescribing 2000-2017.
    Wilkinson S; Douglas I; Stirnadel-Farrant H; Fogarty D; Pokrajac A; Smeeth L; Tomlinson L
    BMJ Open; 2018 Jul; 8(7):e022768. PubMed ID: 30056393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns and satisfaction in patients with type 2 diabetes newly initiating oral monotherapy with antidiabetic drugs in Japan: results from the prospective Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND).
    Tajima A; Tobe K; Eiki JI; Origasa H; Watada H; Shimomura I; Tokita S; Kadowaki T
    BMJ Open Diabetes Res Care; 2022 Dec; 10(6):. PubMed ID: 36585033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of baseline characteristics and clinical course in Japanese patients with type 2 diabetes among whom different types of oral hypoglycemic agents were chosen by diabetes specialists as initial monotherapy (JDDM 42).
    Fujihara K; Igarashi R; Matsunaga S; Matsubayashi Y; Yamada T; Yokoyama H; Tanaka S; Shimano H; Maegawa H; Yamazaki K; Kawai K; Sone H
    Medicine (Baltimore); 2017 Feb; 96(7):e6122. PubMed ID: 28207538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain.
    Conget I; Mauricio D; Ortega R; Detournay B;
    BMJ Open; 2016 Jul; 6(7):e010197. PubMed ID: 27466235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in prescription patterns and doses of oral antidiabetic drugs in Japanese patients with type 2 diabetes (JDDM70).
    Shirabe S; Yamazaki K; Oishi M; Arai K; Yagi N; Sato M; Takeuchi M; Kai T; Maegawa H
    J Diabetes Investig; 2023 Jan; 14(1):75-80. PubMed ID: 36268571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.
    Au PCM; Tan KCB; Lam DCL; Cheung BMY; Wong ICK; Kwok WC; Sing CW; Cheung CL
    JAMA Netw Open; 2023 Jan; 6(1):e2251177. PubMed ID: 36648944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes.
    Levin PA; Wei W; Zhou S; Xie L; Baser O
    J Manag Care Spec Pharm; 2014 May; 20(5):501-12. PubMed ID: 24761822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of oral antidiabetic treatment for type 2 diabetes characterized by drug class, patient characteristics and severity of renal impairment: A Japanese database analysis.
    Kadowaki T; Sarai N; Hirakawa T; Taki K; Iwasaki K; Urushihara H
    Diabetes Obes Metab; 2018 Dec; 20(12):2830-2839. PubMed ID: 29974673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of oral antidiabetic drugs in Japanese working-age patients with type 2 diabetes mellitus: dosing pattern for metformin initiators.
    Kameda T; Kumamaru H; Nishimura S; Kohsaka S; Miyata H
    Curr Med Res Opin; 2020 May; 36(5):749-756. PubMed ID: 32050809
    [No Abstract]   [Full Text] [Related]  

  • 12. Fixed-dose combination antidiabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance.
    Benford M; Milligan G; Pike J; Anderson P; Piercy J; Fermer S
    Adv Ther; 2012 Jan; 29(1):26-40. PubMed ID: 22246944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002-2011 in Japan (JDDM32).
    Oishi M; Yamazaki K; Okuguchi F; Sugimoto H; Kanatsuka A; Kashiwagi A;
    J Diabetes Investig; 2014 Sep; 5(5):581-7. PubMed ID: 25411627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prescribing trend of oral antidiabetic agents for type 2 diabetes in Taiwan: An 8-year population-based study.
    Chu WM; Ho HE; Huang KH; Tsan YT; Liou YS; Wang YH; Lee MC; Li YC
    Medicine (Baltimore); 2017 Oct; 96(43):e8257. PubMed ID: 29068991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A short-term follow-up of glycemic and body weight changes in diabetic patients who replaced dipeptidyl peptidase-4 inhibitors with the sodium-glucose cotransporter 2.
    Huang CH; Huang YY; Hsu BR
    Ann Saudi Med; 2018; 38(6):420-426. PubMed ID: 30531176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan: A real-world administrative database analysis.
    Kashiwagi A; Shoji S; Kosakai Y; Yoshinaga Y; Rokuda M
    J Diabetes Investig; 2024 Mar; 15(3):374-387. PubMed ID: 38112598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of oral diabetes medications on glycated haemoglobin (HbA1c) in Asians in primary care: a retrospective cohort real-world data study.
    Fang HSA; Gao Q; Tan WY; Lee ML; Hsu W; Tan NC
    BMC Med; 2022 Jan; 20(1):22. PubMed ID: 35078484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004-2013.
    Clemens KK; Liu K; Shariff S; Schernthaner G; Tangri N; Garg AX
    Diabetes Obes Metab; 2016 Jun; 18(6):607-14. PubMed ID: 26939711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of effectiveness and drug cost between dipeptidyl peptidase-4 inhibitor and biguanide as the first-line anti-hyperglycaemic medication among Japanese working generation with type 2 diabetes.
    Ihana-Sugiyama N; Sugiyama T; Tanaka H; Ueki K; Kobayashi Y; Ohsugi M
    J Eval Clin Pract; 2020 Feb; 26(1):299-307. PubMed ID: 31161662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.